FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 11, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
| Conference Call and Webcast | |
| Date and Time: | Thursday, August 11, 2022 at 4:30 p.m. ET |
| Domestic: | 1-877-407-0792 |
| International: | 1-201-689-8263 |
| Passcode: | 13730467 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1553842&tp_key=22c148327f |
A replay of the webcast will be archived on the Motus GI website, www.motusgi.com, for 90 days following the event.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
twilliams@lifesciadvisors.com
12 early-career researchers will receive three years of support to carry out projects at the…
WOKING, United Kingdom, Dec. 17, 2025 /PRNewswire/ -- As 2025 draws to a close, IDBS…
BOSTON, Dec. 17, 2025 /PRNewswire/ -- The Center for Information and Study on Clinical Research…
Consumer brands and grocery retailers nationwide join Acosta Group to support MDAJACKSONVILLE, Fla., Dec. 17,…
MACAO, Dec. 17, 2025 /PRNewswire/ -- Concurrent with the 16th Asian Electronics Forum & Global…
Lotus Neuro builds on Insightec's groundbreaking focused ultrasound platform to accelerate next-generation brain therapies globally,…